Who is sponsoring NCT03924804?

NCT03924804 is sponsored by China Medical University, China.

What drugs are being tested in NCT03924804?

Interventions in NCT03924804: Ringer's solution acetate, Ringer's solution acetate, Ringer's solution acetate.

What condition does NCT03924804 study?

NCT03924804 studies Cholecystolithiasis and Thyroid Nodule.

Is NCT03924804 still recruiting?

NCT03924804 is currently completed. Last updated 13 May 2022.

Last reviewed 2022-05-13 · How we verify

NCT03924804

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.

Completed NA Last updated 13 May 2022

What this trial tests

NA trial testing Ringer's solution acetate in Cholecystolithiasis and Thyroid Nodule in 90 participants. Completed in 12 May 2022.

Timeline

19 June 2019

Primary endpoint
12 May 2022

12 May 2022

Quick facts

Lead sponsor	China Medical University, China
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	90
Start date	19 June 2019
Primary completion	12 May 2022
Estimated completion	12 May 2022
Sites	1 location across China

Drugs / interventions tested

Ringer's solution acetate
Ringer's solution acetate
Ringer's solution acetate

Conditions studied

Cholecystolithiasis and Thyroid Nodule — all drugs for Cholecystolithiasis and Thyroid Nodule →

Sponsor

China Medical University, China

Who can join

Adults 18 to 65, any sex, with Cholecystolithiasis and Thyroid Nodule. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the trial was to explore the effect of different infusion volume on perioperative bladder and blood volume in patients undergoing daytime surgery assisted by bladder and vascular ultrasound and transthoracic echocardiography.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other China Medical University, China trials

Trials by the same sponsor.

NCT07519837 — Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics · NA · recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03924804 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China Medical University, China
Last refreshed: 13 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03924804.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing